Briefs: Lupin and Aurobindo Pharma

Lupin updates on shipment of Mirabegron ER Tablets

Strides receives USFDA approval for Sevelamer Carbonate Tablets

Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment

Gland Pharma receives approval for Edaravone Injection

The product is used to treat amyotrophic lateral sclerosis

Moderna posts Q1 2024 revenues at US$167 million

GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)

Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter

Gland Pharma receives approval for cetrorelix acetate for injection

Merck 1Q 2024 sales up 9% to US$ 15.8 billion

Sales reflect continued strong growth in oncology and vaccines

Bristol Myers Squibb and Cellares inks US$ 380 million capacity reservation for the manufacture of CAR T Cell Therapies

Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use

Boehringer Ingelheim introduces NexGard Spectra for dogs in India

NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs

Jubilant Pharmova to close manufacturing operations of Solid dosage formulation facility of Jubilant Cadista USA

The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.